New Dual-Action pill aims to tame type 2 diabetes
NCT ID NCT06144788
First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time
Summary
This study tests an experimental drug, JP-2266, in adults with type 2 diabetes. The drug works by blocking two proteins (SGLT1 and SGLT2) to help lower blood sugar. Participants receive either JP-2266 or a placebo for 12 weeks, and researchers measure changes in HbA1c, a key blood sugar marker.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- JP-2266 (SGLT1/2 inhibitor)
- What this could lead to
- If successful, JP-2266 could offer a new oral option to help lower blood sugar in people with type 2 diabetes.
- What could go wrong
- This is an early phase 2 trial with a small number of participants. The drug may not prove more effective than existing treatments, and side effects are still being evaluated.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
161 people
The number who actually took part.
- Started
-
Nov 2023
- Finished
-
Dec 2024
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
19 to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Adult aged 19 to 80 years 2. Those diagnosed with type 2 diabetes 3. A person who provides diet and exercise therapy for the management of diabetes from 8 weeks before the screening criteria and can continue diet and exercise therapy during the clinical trial 4. Screening Results of the following criteria * 7% ≤ HbA1c ≤ 10% * FPG ≤ 270 mg/dL 5. Patients with 20 \< BMI ≤ 45 kg/㎡ 6. Those who voluntarily signed the informed consent to participate in this study Exclusion Criteria: 1. Any type of diabetes other than type 2 diabetes 2. Screening when the inspection meets the following criteria * AST or ALT more than 3 times the normal upper limit * Total bilirubin exceeds twice the normal upper limit * eGFR \< 60 mL/min/1.73㎡ 3. A person with the following medical history or history of surgery/therapy * Medically significant history of kidney disease: kidney vascular obstruction disease, nephrectomy, kidney transplantation, etc * History of severe gastrointestinal surgery: total gastrectomy, total colon resection, small intestine resection, gastrointestinal anastomosis, gastrointestinal bypass, etc * history of acute pancreatitis or pancreatic surgery * History of undergoing bariatric surgery within 2 years before screening * Diabetic ketoacidosis, diabetic coma or whole marriage within 1 year prior to screening * Urinary tract infections or genital infections within 1 year prior to screening * Alcohol or drug addiction within 1 year prior to screening * A history of severe heart disease (heart failure, unstable angina, myocardial infarction, congestive heart failure symptoms * A person who has a history of significant surgery that causes electrolyte imbalance within 12 weeks before screening, or who is scheduled to undergo significant surgery within 12 weeks after the end of the clinical trial * Hypertension emergency medical history within 12 weeks prior to screening * There is a weight change of more than 10% within 12 weeks prior to screening, and symptoms of polyuria and bipolar disorder * A person with a history of malignancy within 5 years prior to screening However, a complete cure or properly controlled basal cell cancer, squamous cell skin cancer, or cervical intraepithelial cancer is allowed, but the history of bladder cancer cannot participate even if it has been more than 5 years 4. A person who has the following diseases or signs * Dysuria that is not medically controlled due to tense urinary incontinence, neurotic bladder, prostate hypertrophy, or symptoms of anuria, oliguria, urinary retention * Severe diabetic complications (proliferative diabetic retinopathy, nephropathy above stage 4 or severe diabetic neuropathy) * Chronic diseases that require continuous use of diuretics, systemic steroids or immunosuppressants (alveolar administration, injection) * Active liver disease, hepatitis, liver failure or cirrhosis * Patients with pituitary or adrenal insufficiency * Severe infections requiring the use of persistent antibiotics or immunotherapy drugs, and significant clinically trauma * an unstable mental illness that is not medically controlled * Severe gastrointestinal diseases: active ulcers, gastrointestinal/intestinal bleeding, active inflammatory bowel syndrome, patients with biliary obstruction, active gastritis not controlled by medication, etc 5. A person who has a history of hypersensitivity to the ingredients of a clinical trial drug, SGLT1/SGLT2 inhibitor or SGLT-2 inhibitor 6. Pregnant or lactating women 7. Participants in interventional clinical trials subject to other IP or medical devices within 12 weeks prior to screening 8. If the investigator is deemed unsuitable for the subject of this clinical trial due to other reasons
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Type 2 diabetes mellitus are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Severance Hospital
Seoul, Seodaemun-gu, 03722, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Cost-Effectiveness and implementation of integrated Diabetes-Oral health care in oman: a health belief Model-Based intervention to enhance clinical, behavioral, and exploratory oral microbiome in health system outcomes in type 2 diabetes
- Can a damaged kidney change how a drug works?
- Can ultrasound spot early joint wear in diabetic nerve damage?
- Can a 15-Day wearable sensor keep blood sugar on target?
- Nanoparticle cleaning may calm pain after failed root canals in diabetic patients
- Stomach sensor may unmask hidden effects of weight-loss drugs